FXR activation often counteracts OPN expression, resulting in the suppression of FAK/AKT and induction of CYP7A1 liver expression [25], which eventually improves NASH-associated liver injury. The gene discussed is PTK2; the disease is metabolic dysfunction-associated steatohepatitis.